Core Insights - GSK reported quarterly earnings of $1.13 per share, exceeding the Zacks Consensus Estimate of $1.08 per share, and showing an increase from $1.09 per share a year ago, resulting in an earnings surprise of 4.63% [1] - The company posted revenues of $9.46 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.85%, but showing growth from $9.34 billion year-over-year [2] - GSK's stock has increased by approximately 15.2% since the beginning of the year, contrasting with a -5.5% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05, with projected revenues of $10.04 billion, and for the current fiscal year, the EPS estimate is $4.24 on revenues of $40.62 billion [7] - The estimate revisions trend for GSK is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which GSK belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Sage Therapeutics reported a quarterly loss of $1.01 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.99, and an improvement from a loss of $1.80 per share a year ago [1] - The company posted revenues of $14.06 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.67%, but showing growth from $7.9 million in the same quarter last year [2] - Over the last four quarters, Sage Therapeutics has not surpassed consensus EPS estimates, although it has topped consensus revenue estimates twice [2] Stock Performance - Sage Therapeutics shares have increased by approximately 43.1% since the beginning of the year, contrasting with a decline of 6% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.95 on revenues of $17.11 million, and for the current fiscal year, it is -$3.38 on revenues of $81.59 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Sage Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Wall Street expects a year-over-year increase in earnings on higher revenues when Arcutis Biotherapeutics, Inc. (ARQT) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are be ...

Another stock in the Medical sector, Doximity (DOCS) , has outperformed the sector so far this year. The stock's year-to-date return is 6.2%. In Doximity's case, the consensus EPS estimate for the current year increased 13.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Coya Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual stocks and currently sits at #76 in the Zacks Industry Rank. Thi ...

Core Viewpoint - Repligen (RGEN) reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing an increase from $0.28 per share a year ago, indicating a positive earnings surprise of 11.43% [1][2] Financial Performance - The company achieved revenues of $169.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.85% and up from $151.35 million year-over-year [2] - Over the last four quarters, Repligen has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance and Outlook - Repligen shares have declined approximately 0.2% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $174.55 million, and for the current fiscal year, it is $1.69 on revenues of $701.98 million [7] - The estimate revisions trend for Repligen is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - NeoGenomics reported break-even quarterly earnings per share, surprising the market as the consensus estimate was a loss of $0.02, marking a 100% earnings surprise [1] - The company posted revenues of $168.04 million for the quarter ended March 2025, which was 1.66% below the Zacks Consensus Estimate, but an increase from $156.24 million year-over-year [2] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Group 2 - NeoGenomics shares have declined approximately 39.5% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.04 on revenues of $183.07 million, and for the current fiscal year, it is $0.16 on revenues of $738.2 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact NeoGenomics' stock performance [5][6]

Urogen Pharma (URGN) shares ended the last trading session 14.1% higher at $11.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.9% loss over the past four weeks.The stock rallied after the company presented multiple data at the annual meeting of the American Urological Association 2025 on its pipeline candidates that are being studied for different cancer indications.This company is expected to post quarterly ...

Company Overview - ADC Therapeutics SA (ADCT) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ended March 2025, with a consensus outlook indicating a quarterly loss of $0.38 per share, reflecting a +32.1% change from the previous year [1][3] - Expected revenues for ADC Therapeutics are projected at $18.15 million, which is a slight increase of 0.6% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 8.33% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4] - The Most Accurate Estimate for ADC Therapeutics aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [6][8] - ADC Therapeutics currently holds a Zacks Rank of 3, making it challenging to predict a definitive earnings beat [11] Historical Performance - In the last reported quarter, ADC Therapeutics was expected to post a loss of $0.35 per share but actually reported a loss of $0.29, resulting in a surprise of +17.14% [12] - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Cardiff Oncology (CRDF) is expected to report a loss of $0.19 per share for the same quarter, indicating a year-over-year change of +13.6% [17] - Cardiff Oncology's revenue is projected to be $0.17 million, down 19.1% from the previous year, but it has an Earnings ESP of 24.32% and a Zacks Rank of 2, suggesting a higher likelihood of beating the consensus EPS estimate [18]

Certara, Inc. (CERT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 5. On ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 5, 2025, might help the stock move higher if these key number ...